Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report outlays ...
In addition to AIS, DiaMedica (DMA.V) (DMCAF) is also developing DM199 for the treatment of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) or Diabetic nephropathy (DN) is one of the most ...
A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.
Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial. C. Ola Landgren, MD, PhD: The once-weekly and twice-weekly ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...
BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership, has announced the launch of a 5-year project with the aim to improve prevention and management ...
LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing ...
In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the ...
Researchers found that finerenone, compared with placebo, decreases sudden death risk in patients with cardio-kidney-metabolic syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results